MK-8353   Click here for help

GtoPdb Ligand ID: 9974

Synonyms: MK8353 | SCH900353
PDB Ligand
Compound class: Synthetic organic
Comment: MK-8353 (formerly know as SCH900353) is an orally bioavailable dual mechanism ERK1/2 inhibitor, i.e. it inhibits ERK1/2 catalytic activity and phosphorylation of ERK1/2 [1]. It has improved pharmacokinetic properties in comparison to SCH772984 (a preclinical ERK1/2 inhibtor tool compound) and has shown preliminary anti-tumour efficacy in patients with BRAF or RAS mutated metastatic melanoma and colorectal cancers.
(Note: ERK1= MAPK3, ERK2= MAPK1).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 12
Topological polar surface area 159.46
Molecular weight 691.31
XLogP 5.1
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CSC1(CCN(C1)CC(=O)N1CCC(=CC1)c1ccc(cc1)c1ncn(n1)C)C(=O)Nc1ccc2c(c1)c(n[nH]2)c1ccc(nc1)OC(C)C
Isomeric SMILES CS[C@]1(CCN(C1)CC(=O)N1CCC(=CC1)c1ccc(cc1)c1ncn(n1)C)C(=O)Nc1ccc2c(c1)c(n[nH]2)c1ccc(nc1)OC(C)C
InChI InChI=1S/C37H41N9O3S/c1-24(2)49-32-12-9-28(20-38-32)34-30-19-29(10-11-31(30)41-42-34)40-36(48)37(50-4)15-18-45(22-37)21-33(47)46-16-13-26(14-17-46)25-5-7-27(8-6-25)35-39-23-44(3)43-35/h5-13,19-20,23-24H,14-18,21-22H2,1-4H3,(H,40,48)(H,41,42)/t37-/m0/s1
No information available.
Summary of Clinical Use Click here for help
A Phase 1 study of MK-8353 as a single agent in patients with advanced solid tumours (NCT01358331) was terminated; results from this trial were published by MOschos et al. (2018) [1]. has trial number NCT01358331 listed as 'recruiting', and this study is designed to evaluate the eficacy of MK-8353 in combination with the approved PD-1 checkpoint inhibitor pembrolizumab, in patients with advanced colorectal cancer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01358331 A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) Phase 1 Interventional Merck Sharp & Dohme Corp.
NCT02972034 Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) Phase 1 Interventional Merck Sharp & Dohme Corp.